Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15616809 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL15130583 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL13434053 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL16329221 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL14330842 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL13612332 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL16075605 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL13497925 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL13449873 | 1.00 | MGMT (0.41) | MGMTABCG2 | |
| SCHEMBL31395477 | 1.00 | MGMT (0.41) | MGMTABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107248-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-04-20 | — | — | US | disclosed |
| US-20160030585-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030585-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | MGMT 3988/4885ABCG2 2120/4885 |
| US-20170107248-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | PTMS, DNPEP, ANPEP | MGMT 1625/4885ABCG2 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.